Funke Andreas, Danowski Adriana, de Andrade Danieli Castro Oliveira, Rêgo Jozelia, Levy Roger Abramino
Universidade Federal do Paraná - UFPR, Hospital de Clínicas, Curitiba, PR, Brasil.
Hospital Federal dos Servidores do Estado - HFSE, Rio de Janeiro, RJ, Brasil.
J Vasc Bras. 2017 Apr-Jun;16(2):140-149. doi: 10.1590/1677-5449.011416.
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by recurrent arterial or venous thrombosis and/or gestational morbidity and by the presence of antiphospholipid antibodies. It can also cause other vascular manifestations such as microangiopathy, chronic arteriopathy and catastrophic APS (CAPS). Certain laboratory tests for the syndrome (for example, the lupus anticoagulant test) can be affected by the use of anticoagulant agents, making diagnosis more difficult. The pathophysiology of APS is complex, and several mechanisms of pathogenesis related to coagulation, endothelium, and platelets are discussed in this article. We conclude by discussing treatment of APS according to the presence and type of clinical manifestations, use of direct oral anticoagulants (DOAs), and perioperative management of patients with APS.
抗磷脂综合征（APS）是一种系统性自身免疫性疾病，其特征为反复发生动脉或静脉血栓形成和/或妊娠并发症，并存在抗磷脂抗体。它还可引起其他血管表现，如微血管病、慢性动脉病和灾难性抗磷脂综合征（CAPS）。该综合征的某些实验室检查（例如狼疮抗凝物试验）可能会受到抗凝剂使用的影响，从而使诊断更加困难。APS的病理生理学很复杂，本文讨论了与凝血、内皮和血小板相关的几种发病机制。我们通过根据临床表现的存在和类型、直接口服抗凝剂（DOA）的使用以及APS患者的围手术期管理来讨论APS的治疗作为总结。
